This paper is in the following e-collection/theme issue:

Longitudinal and Cohort Studies in Public Health (413) Gastroenterology and Hepatology (131)

Published on in Vol 9 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/45050, first published .
The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study

The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study

The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study

Authors of this article:

Suosu Wei1 Author Orcid Image ;   Jian Song2 Author Orcid Image ;   Yujie Xie3 Author Orcid Image ;   Junzhang Huang4 Author Orcid Image ;   Jianrong Yang5 Author Orcid Image
Article Authors Cited by (6) Tweetations (2) Metrics

Journals

  1. Li Y, Wu S, Gao J, Zhang Y, Zuo Y, Tian X, Chen S, Xing A, Wang A, He Y. Association of Stroke With Metabolic Dysfunction–Associated Fatty Liver Disease With and Without CKD. American Journal of Kidney Diseases 2024;83(4):477 View
  2. Nardolillo M, Rescigno F, Bartiromo M, Piatto D, Guarino S, Marzuillo P, Miraglia del Giudice E, Di Sessa A. Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective. World Journal of Gastroenterology 2024;30(15):2081 View
  3. Yang D, Ma L, Cheng Y, Shi H, Liu Y, Shi C. Utility of Anthropometric Indexes for Detecting Metabolic Syndrome in Resource-Limited Regions of Northwestern China: Cross-Sectional Study. JMIR Public Health and Surveillance 2024;10:e57799 View
  4. Liu W, Sun X. Does metabolic dysfunction-associated fatty liver disease increase the risk of chronic kidney disease? A meta-analysis of cohort studies. BMC Nephrology 2024;25(1) View
  5. Katsiki N, Kolovou G, Vrablik M. Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease. Current Cardiology Reports 2025;27(1) View
  6. Zisis M, Chondrogianni M, Androutsakos T, Rantos I, Oikonomou E, Chatzigeorgiou A, Kassi E. Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment. Biomolecules 2025;15(3):324 View